anti-doping analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
To date, many studies have been conducted on the benefits of selenium intake in reducing the risk of cancer incidence at the nutritional level, indicating that likely selenium functions as an immunostimulator, i.e. reversing the immunosuppression in tumour microenvironment towards antitumour immunity by activating immune cells (e.g. M1 macrophages and CD8+ T-lymphocytes, the elevated number of neutrophils and activated cytotoxic NK cells) and releasing pro-inflammatory cytokines such as IFNγ and TNFα.
=== Serotonin 5-HT2A receptor antagonists === Serotonin 5-HT2A receptor antagonists such as ritanserin, ketanserin, eplivanserin, volinanserin, nelotanserin, and pimavanserin have been studied and developed to improve sleep. They do not improve sleep onset, but have been found to increase slow wave sleep (deep sleep) and reduce nighttime awakenings. Conversely, improvement in subjective sleep ratings have been more mixed. Ultimately no selective serotonin 5-HT2A receptor antagonists have been approved for treatment of insomnia. The only selective serotonin 5-HT2A receptor antagonist to be approved for any indication is pimavanserin for treatment of Parkinson's disease psychosis. Besides selective serotonin 5-HT2A receptor antagonists however, many non-selective agents used as hypnotics show serotonin 5-HT2A receptor antagonism, for instance antidepressants like trazodone, mirtazapine, and amitriptyline, antipsychotics like quetiapine and olanzapine, and antihistamines like hydroxyzine and cyproheptadine.
== Chemistry == Teicoplanin (TARGOCID, marketed by Sanofi Aventis Ltd) is actually a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1 — a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety — β-D-glucosamine — and differ only by the length and conformation of a side-chain attached to it. Teicoplanin A2-4 and RS-3 have chiral side chains while all other side chains are achiral. Teicoplanin A3 lacks both the side chains as well as the β-D-glucosamine moiety. The structures of the teicoplanin core and the side-chains that characterize the five major as well as four minor teicoplanin compounds are shown below.
== History == Bob Hoffman launched Hoffman's Hi-Proteen Fudge and Hoffman's Hi-Proteen Cookies in the early 1950s, and competitor Joe Weider launched Candy Food Bars with bodybuilder Dave Draper on the packaging in the late 1960s. Pillsbury Space Food Bars and the bars by Tiger's Milk both came to market in the 1960s. Though they had protein, they were marked as energy or nutrition bars. PowerBar, invented in California in 1986, was an early protein bar.
Sources: en.wikipedia.org
Despite criticism and international opposition to his controversial anti-narcotics drive, Duterte's domestic approval rating remained relatively high throughout his presidency. Duterte began his presidency with a high trust rating of 79% and 91% (the highest of any Philippine official since 1999), from pollsters Social Weather Stations (SWS) and Pulse Asia, respectively. His net satisfaction rating reached its lowest at 45% in July 2018, attributed to inflation during the period as well as Duterte calling God "stupid" for the concept of original sin in the Bible; eventually, his satisfaction rating rose to 60% by the end of the year. Halfway through his term, Duterte's approval rating reached 79%, the highest among his predecessors at this stage in their presidencies. It rose to 87% by the end of 2019 due to the successful hosting of the 2019 Southeast Asian Games as well as the administration's poverty reduction programs. Amid the COVID-19 pandemic, Pulse Asia reported in September 2020 that 84% of Filipinos approved of the administration's efforts to contain the virus and provide assistance to those who lost their jobs; 92% of the poll respondents also agreed Duterte had "done well" in preventing the contagion in the country. Duterte ended 2021 with an approval rating of 60%, wherein higher net satisfaction was observed among those who have been or are willing to get vaccinated. Duterte maintained his high approval and trust ratings as he approached the end of his term.
Starting in 2001, the government introduced a series of programmes to increase fertility, including paid maternity leave, childcare subsidies, tax relief and rebates, one-time cash gifts, and grants for companies that implement flexible work arrangements; nevertheless, live births have continued to decline, hitting a record low in 2022. Singapore's immigration policy is designed to alleviate the decline and maintain its working-age population. 91% of resident households (i.e. households headed by a Singapore citizen or permanent resident) own the homes they live in, and the average household size is 3.43 persons (which include dependants who are neither citizens nor permanent residents). However, due to scarcity of land, 78.7% of resident households live in subsidised, high-rise, public housing apartments developed by the Housing and Development Board (HDB). Also, 75.9% of resident households live in properties that are equal to, or larger than, a four-room (i.e. three bedrooms plus one living room) HDB flat or in private housing. Live-in foreign domestic workers are quite common in Singapore, with about 224,500 foreign domestic workers there, as of December 2013.
Pocket watches are uncommon in the present day, having first been superseded by wristwatches and later by smartphones. Until early in the 20th century, though, the pocket watch remained predominant for men, with the wristwatch considered feminine and unmanly. In men's fashions, pocket watches began to be superseded by wristwatches around the time of World War I, when officers in the field began to appreciate that a watch worn on the wrist was more easily accessed than one kept in a pocket. A watch of transitional design, combining features of pocket watches and modern wristwatches, was called a "trench watch" or "wristlet". The more accurate pocket watches continued to be widely used in railroading even as their popularity declined elsewhere. Quartz pocket watches are available in the present day, retaining the form and function of the original pocket watches while using a quartz crystal as opposed to the traditional fully-mechanical movement. For a few years in the late 1970s and early 1980s three-piece suits for men returned to fashion, and this led to small resurgence in pocket watches, as some men actually used the vest pocket for its original purpose. Since then, some watch companies continue to make pocket watches. As vests have long since fallen out of fashion (in the US) as part of formal business wear, the only available location for carrying a watch is in a trouser pocket.
Sources: en.wikipedia.org
==== Genomic phylostratigraphy ==== Genomic phylostratigraphy involves examining each gene in a focal, or reference, species and inferring the presence or absence of ancestral homologs through the use of the BLAST sequence alignment algorithms or related tools. Each gene in the focal species can be assigned an age (aka "conservation level" or "genomic phylostratum") that is based on a predetermined phylogeny, with the age corresponding to the most distantly related species in which a homolog is detected. When a gene lacks any detectable homolog outside of its own genome, or close relatives, it is said to be a novel, taxonomically restricted or orphan gene. Phylostratigraphy is limited by the set of closely related genomes that are available, and results are dependent on BLAST search criteria. In addition, it is often difficult to determine based on lack of observed sequence similarity whether a novel gene has emerged de novo or has diverged from an ancestral gene beyond recognition, for instance following a duplication event. This was pointed out by a study that simulated the evolution of genes of equal age and found that distant orthologs can be undetectable for rapidly evolving genes. On the other hand, when accounting for changes in the rate of evolution in young regions of genes, a phylostratigraphic approach was more accurate at assigning gene ages in simulated data. Subsequent studies using simulated evolution found that phylostratigraphy failed to detect an ortholog in the most distantly related species for 13.9% of D. melanogaster genes and 11.4% of S.
At one week post-procedure, the patients resumed using the external vacuum tissue-expander for 10 hours daily, until the next fat grafting session; 2–5 outpatient procedures, 6–16 weeks apart, were required until the plastic surgeon and the patient were satisfied with the volume, form, and feel of the reconstructed breasts. The follow-up mammogram and MRI examinations found neither defects (necrosis) nor abnormalities (neoplasms). At six months post-procedure, the reconstructed breasts had a natural form, look, and feel, and the stable breast-volumes ranged 300–600 ml per breast. The post-procedure mammographies indicated normal, fatty breasts with well-vascularized fat, and few, scattered, benign oil cysts. The occurred complications included pneumothorax and transient cysts.
=== Liquid chromatography === DESI can be coupled to ultra-fast liquid chromatography using an LC eluent splitting strategy. It is a strategy through a tiny orifice on an LC capillary tube. There is negligible dead volume and back pressure that allows for almost real time mass spectrometry detection with a fast elution and purification. This coupling can be used to ionize a wide range of molecules, from small organics to high mass proteins. This is different from ESI (electrospray ionization) in that it can be used to directly analyze salt-containing sample solutions without requiring “make-up” solvents/ acids to be doped into the sample. This set up allows for a high flow rate without splitting. The high resolution that is accomplished by reverse-phase HPLC can be combined with this procedure to produce high throughput screening of natural products as well. The incorporation of the electrochemistry component helps with ionization efficiency via the electrochemical conversion. This method is proved better than ESI in the fact that you don't have to separate the small potential that is applied to the cell from the potential on the spray in DESI. DESI also shows a better tolerance to inorganic salt electrolytes and you can use traditional solvents used in electrolysis.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.